Can you provide OEM or ODM services?

Yes, OEM and ODM services are available for this product.

What are the payment terms for this product?

Payment terms include LC, T/T, D/P, PayPal, Western Union, and Small-amount payment.

What is the average lead time for production?

The average lead time is one month for both peak season and off season.

Veterinary API Raw Materials Colistin Sulphate

Name: Veterinary API Raw Materials Colistin Sulphate
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1952138112

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$22.00-27.00

100 kg

Sample price:US$3.00/kg.Request sample

Product profile

Customization

Available

Varieties

Growth Promoting Medicine

Component

Chemical Synthetic Drugs

Type

The First Class

Pharmacodynamic Influential Factors

Incompatibility

Storage Method

Light Proof

Transport Package

25kg/Bag

Specification

25kg/bag

Origin

Zhengzhou, Henan Province

HS Code

3004909099

Production Capacity

30000 Tons /Year

Key features

Strong Anti-Gram Negative Activity: Highly effective against E. coli, Salmonella, and Pseudomonas aeruginosa.

Low Resistance Risk: Almost no drug resistance found; no resistance to factor R detected.

Synergistic Effects: Enhances efficacy when combined with bacitracin zinc, gentamicin, and penicillin.

No Residue Concerns: Poor intestinal absorption ensures no residue in livestock products when administered orally.

Growth Promotion: Promotes livestock and poultry growth while preventing infectious enteritis.

High Purity Assay: Assay not less than 19000IU/mg, tested per Chinese Veterinary Pharmacopoeia.

Customizable OEM/ODM: OEM and ODM services available for tailored product requirements.

Stable Shelf Life: 36 months shelf life when stored in a cool, dry, and dark location.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤11.82h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.